Cargando…

Splicing Factor DDX23, Transcriptionally Activated by E2F1, Promotes Ovarian Cancer Progression by Regulating FOXM1

Ovarian carcinoma remains the most lethal gynecological carcinoma. Abnormal expression of splicing factors is closely related to the occurrence and development of tumors. The DEAD-box RNA helicases are important members of the splicing factor family. However, their role in the occurrence and progres...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Chen, Li, Yingwei, Qiu, Chunping, Chen, Jingying, Wu, Huan, Wang, Qiuman, Ma, Xinyue, Song, Kun, Kong, Beihua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8710544/ https://www.ncbi.nlm.nih.gov/pubmed/34966670 http://dx.doi.org/10.3389/fonc.2021.749144

Ejemplares similares

Oncolytic adenovirus with MUC16-BiTE shows enhanced antitumor immune response by reversing the tumor microenvironment in PDX model of ovarian cancer
por: Wang, Qiuman, et al.
Publicado: (2022)

Overexpression of PRC1 indicates a poor prognosis in ovarian cancer
por: Bu, Hualei, et al.
Publicado: (2020)

TTK inhibition increases cisplatin sensitivity in high-grade serous ovarian carcinoma through the mTOR/autophagy pathway
por: Qi, Gonghua, et al.
Publicado: (2021)

HJURP Promotes Malignant Progression and Mediates Sensitivity to Cisplatin and WEE1-inhibitor in Serous Ovarian Cancer
por: Dou, Zhiyuan, et al.
Publicado: (2022)

SF3B4 promotes ovarian cancer progression by regulating alternative splicing of RAD52
por: Diao, Yuchao, et al.
Publicado: (2022)

Clinical features and prognostic factors analysis of intravenous leiomyomatosis
por: Chen, Jingying, et al.
Publicado: (2023)

MEX3A promotes the malignant progression of ovarian cancer by regulating intron retention in TIMELESS
por: Li, Fangfang, et al.
Publicado: (2022)

Splicing factor USP39 promotes ovarian cancer malignancy through maintaining efficient splicing of oncogenic HMGA2
por: Wang, Shourong, et al.
Publicado: (2021)

IQGAP3 promotes cancer proliferation and metastasis in high-grade serous ovarian cancer
por: Dongol, Samina, et al.
Publicado: (2020)

Small molecule targeting FOXM1 DNA binding domain exhibits anti-tumor activity in ovarian cancer
por: Zhang, Zaixin, et al.
Publicado: (2022)

FOXM1 Modulates Cisplatin Sensitivity by Regulating EXO1 in Ovarian Cancer
por: Zhou, Jinhua, et al.
Publicado: (2014)

FBLN5 is targeted by microRNA-27a-3p and suppresses tumorigenesis and progression in high-grade serous ovarian carcinoma
por: Li, Rongrong, et al.
Publicado: (2020)

FAM64A promotes HNSCC tumorigenesis by mediating transcriptional autoregulation of FOXM1
por: Zhao, Xinyuan, et al.
Publicado: (2022)

FOXM1: Functional Roles of FOXM1 in Non-Malignant Diseases
por: Zhang, Zhenwang, et al.
Publicado: (2023)

Inhibition of SF3B1 improves the immune microenvironment through pyroptosis and synergizes with αPDL1 in ovarian cancer
por: Wang, Shourong, et al.
Publicado: (2023)

The splicing factor SF3B4 drives proliferation and invasion in cervical cancer by regulating SPAG5
por: Li, Yingwei, et al.
Publicado: (2022)

DDX17‐regulated alternative splicing that produced an oncogenic isoform of PXN‐AS1 to promote HCC metastasis
por: Zhou, Hong‐Zhong, et al.
Publicado: (2021)

PBK, targeted by EVI1, promotes metastasis and confers cisplatin resistance through inducing autophagy in high-grade serous ovarian carcinoma
por: Ma, Hanlin, et al.
Publicado: (2019)

Effect of taxol on the expression of FoxM1 ovarian cancer-associated gene
por: LIU, ZENG, et al.
Publicado: (2016)

FOXM1: A Multifunctional Oncoprotein and Emerging Therapeutic Target in Ovarian Cancer
por: Liu, Cassie, et al.
Publicado: (2021)

The cell-penetrating FOXM1 N-terminus (M1-138) demonstrates potent inhibitory effects on cancer cells by targeting FOXM1 and FOXM1-interacting factor SMAD3
por: Zhang, Zhenwang, et al.
Publicado: (2019)

DDX23-Linc00630-HDAC1 axis activates the Notch pathway to promote metastasis
por: Mao, Guozhang, et al.
Publicado: (2017)

Kallistatin inhibits tumour progression and platinum resistance in high-grade serous ovarian cancer
por: Wu, Huan, et al.
Publicado: (2019)

Prognostic significance of FOXM1 expression and antitumor effect of FOXM1 inhibition in synovial sarcomas
por: Maekawa, Akira, et al.
Publicado: (2016)

FOXM1 confers to epithelial-mesenchymal transition, stemness and chemoresistance in epithelial ovarian carcinoma cells
por: Chiu, Wen-Tai, et al.
Publicado: (2014)

Correction to: Kallistatin inhibits tumour progression and platinum resistance in high-grade serous ovarian cancer
por: Wu, Huan, et al.
Publicado: (2020)

Expression of FOXM1 and PLK1 predicts prognosis of patients with hepatocellular carcinoma
por: Fan, Weiqiang, et al.
Publicado: (2022)

MiR-501 promotes tumor proliferation and metastasis by targeting HOXD10 in endometrial cancer
por: Sun, Xiaomei, et al.
Publicado: (2021)

DDX5 and DDX17—multifaceted proteins in the regulation of tumorigenesis and tumor progression
por: Xu, Kun, et al.
Publicado: (2022)

Prognostic Significance of Forkhead Box M1 (FOXM1) Expression and Antitumor Effect of FOXM1 Inhibition in Angiosarcoma
por: Ito, Takamichi, et al.
Publicado: (2016)

FOXM1 is regulated by DEPDC1 to facilitate development and metastasis of oral squamous cell carcinoma
por: Qiu, Jing, et al.
Publicado: (2022)

Honokiol is a FOXM1 antagonist
por: Halasi, Marianna, et al.
Publicado: (2018)

Overexpression of FOXM1 is associated with metastases of nasopharyngeal carcinoma
por: Jiang, Lizhu, et al.
Publicado: (2014)

FOXM1c promotes oesophageal cancer metastasis by transcriptionally regulating IRF1 expression
por: Zhou, Yuzhen, et al.
Publicado: (2018)

FOXM1D potentiates PKM2‐mediated tumor glycolysis and angiogenesis
por: Zhang, Wei, et al.
Publicado: (2021)

CCNG1 (Cyclin G1) regulation by mutant‐P53 via induction of Notch3 expression promotes high‐grade serous ovarian cancer (HGSOC) tumorigenesis and progression
por: Xu, Ying, et al.
Publicado: (2018)

BET Bromodomain Inhibition as a Therapeutic Strategy in Ovarian Cancer by Downregulating FoxM1
por: Zhang, Zhenfeng, et al.
Publicado: (2016)

Corrigendum: DDX5 and DDX17—multifaceted proteins in the regulation of tumorigenesis and tumor progression
por: Xu, Kun, et al.
Publicado: (2023)

MNK1 and MNK2 enforce expression of E2F1, FOXM1, and WEE1 to drive soft tissue sarcoma
por: Ke, Xin-Yu, et al.
Publicado: (2021)

Knockdown of TRIM44 inhibits the progression of ovarian cancer and is related to the FOXM1-EZH2 signaling pathway
por: Meng, Fanling, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_0m5ss8k1cjnc3bj5e7v64std2r